Potential use of vanadium compounds in therapeutics

Current Medicinal Chemistry

Volumn 17, Issue 31, 2010, Pages 3632-3642

  Barrio, D A ^a   Etcheverry, S B ^a  

^a FACULTAD DE CIENCIAS EXACTAS   (Argentina)

Author keywords

Antitumoral; Cardioprotection; ERK and PI3 K pathways; Insuinmimics; Intracellular pathways; Osteogenic; Oxidative stress; Vanadium compounds

Indexed keywords

ACETYLACETONATE VANADIUM; ANTINEOPLASTIC AGENT; BIS(ETHYLMALTOLATO)OXOVANADIUM; BIS(MALTOLATO)OXOVANADIUM; GROWTH FACTOR; INSULIN; METVAN; UNCLASSIFIED DRUG; VANADATE SODIUM; VANADIC ACID; VANADIUM DERIVATIVE; VANADYL SULFATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHELATION; DIABETES MELLITUS; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; CARDIOTONIC AGENTS; CHELATING AGENTS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; OSTEOGENESIS; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; VANADIUM; VANADIUM COMPOUNDS;

EID: 78449263078     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793213805     Document Type: Article

References (177)

1. Nielsen, F.H. In: Metal Ions in Biological Systems. Vanadium and its role in life, Sigel, H. and Sigel, A. Ed., Marcel Dekker INC: New York, 1995, pp. 543-73.
2. Slebodnicj, C.; Hamstra, B.J.; Pecoraro, V.L. Modeling the biological chemistry of vanadium: structural and reactivity studies elucidating biological function, Struct. Bond., 1997, 89, 51-107.
3. Srivastava, K.; Mehdi, M.Z. Insulino-mimetic and anti-diabetic effects of vanadium compounds. Diabetic Med., 2004, 22, 2-13.
4. Cortizo, A.M.; Etcheverry, S.B. Vanadium derivatives act as growth factor-mimetic compounds upon differentiation and proliferation of osteoblast-like UMR106 cells. Mol. Cell Biochem., 1995, 145, 97-102.
5. Barrio, D.A.; Etcheverry, S.B. Vanadium and bone development: putative signaling pathways. Can. J. Physiol. Pharmacol., 2006, 84, 677-86.
6. Djordjevic, C.; Wampler, G.L. Antitumor activity and toxicity of peroxo heteroligand vanadates(V) in relation to biochemistry of vanadium. J. Inorg. Biochem., 1985, 25, 51-5.
7. Evangelou, A.M. Vanadium in cancer treatment. Crit. Rev. Oncol. Hematol., 2002, 42, 249-65.
8. Kris-Etherton, P. M.; Hecker, K. D.; Bonanome, A.; Coval, S. M.; Binkoski, A. E.; Hilpert, K. F., Griel, A. E.; Etherton, T. D. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am. J. Med., 2002, 113, 71-88.
9. Bhuiyan, M.S.; Fukunaga, K. Cardioprotection by vanadium compounds targeting Akt-mediated signaling. J. Pharmacol. Sci., 2009, 110, 1-13.
10. Shioda, N.; Han, F.; Fukunaga, K. Role of Akt and ERK signaling in the neurogenesis following brain ischemia. Int. Rev. Neurobiol., 2009, 85, 375-87.
11. Barceloux, D.G. Vanadium. Clin. Toxicol., 1999, 37, 265-278.
12. Badmaev, V.; Prakash, S.; Majeed, M. Vanadium: a review of its potential role in the fight against diabetes. J. Altern. Complement Med., 1999, 5, 273-91.
13. Byrne, A.R.; Kosta, L. Vanadium in foods and in human body fluids and tissues. Sci. Total Environ., 1978, 10, 17-30.
14. Nechay, B.R.; Nanninga, L.B.; Nechay, P.S. Vanadyl (IV) and vanadate (V) binding to selected endogenous phosphate, carboxyl, and amino ligands; calculations of cellular vanadium species distribution. Arch. Biochem. Biophys., 1986, 251, 128-38.
15. Nielsen, F.H. New essential trace elements for the life sciences. Biol. Trace Elem. Res., 1990, 26-27, 599-611.
16. Macara, I.G.; Kustin, K.; Cantley, L.C. Glutathione reduces cytoplasmic vanadate. Mechanism and physiological implications. Biochim. Biophys. Acta, 1980, 629, 95-106.
17. Lyonnet, B.M.; Martin, E. L'emploi therapeutique des derives du vanadium. La Presse Medicale, 1899, 1, 191-192.
18. Shechter, Y. Insulin-mimetic effects of vanadate. Possible implications for future treatment of diabetes. Diabetes, 1990, 39, 1-5.
19. McNeill, J.H.; Yuen, V.G.; Dai, S.; Orvig, C. Increased potency of vanadium using organic ligands. Mol. Cell Biochem., 1995, 153, 175-80.
20. Tolman, E.L.; Barris, E.; Burns, M.; Pansini, A.; Partridge, R. Effects of vanadium on glucose metabolism in vitro. Life Sci., 1979, 25, 1159-64.
21. Shechter, Y.; Karlish, S.J. Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions. Nature, 1980, 284, 556-8.
22. Heyliger, C.E.; Tahiliani, A.G.; McNeill, J.H. Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science, 1985, 227, 1474-1477.
23. Meyerovitch, J.; Farfel, Z.; Sack, J.; Shechter, Y. Oral administration of vanadate normalizes blood glucose levels in streptozotocintreated rats. Characterization and mode of action. J. Biol. Chem., 1987, 262, 6658-62.
24. Cantley, L.C. Jr; Aisen, P. The fate of cytoplasmic vanadium. Implications on (NA,K)-ATPase inhibition. J. Biol. Chem., 1979, 254, 1781-1784.
25. Degani, H.; Gochin, M.; Karlish, S.J.; Shechter, Y. Electron paramagnetic resonance studies and insulin-like effects of vanadium in rat adipocytes. Biochemistry, 1981, 20, 5795-9.
26. Li, J.; Elberg, G.; Crans, D.C.; Shechter, Y. Evidence for the distinct vanadyl(+4)-dependent activating system for manifesting insulin-like effects. Biochem., 1996, 35, 8314-8318.
27. Sakurai, H.; Shimomura, S.; Fukuzawa, K.; Ishizu, K. Detection of oxovanadium (IV) and characterization of its ligand environment in subcellular fractions of the liver of rats treated with pentavalent vanadium(V). Biochem. Biophys. Res. Commun., 1980, 96, 293-8.
28. Llobet, J.M.; Domingo, J.L. Acute toxicity of vanadium compounds in rats and mice. Toxicol. Lett., 1984, 23, 227-231.
29. Ramanadham, S.; Mongold, J.J.; Brownsey, R.W.; Cros, G.H.; McNeill, J.H. Oral vanadyl sulfate in treatment of diabetes mellitus in rats. Am. J. Physiol., 1989, 257, H904-11.
30. Brichard, S.M.; Pottier, A.M.; Henquin, J.C. Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats. Endocrinology, 1989, 125, 2510-6.
31. Brichard, S.M.; Bailey, C.J.; Henquin, J.C. Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes, 1990, 39, 1326-32.
32. Meyerovitch, J.; Rothenberg, P.; Shechter, Y.; Bonner-Weir, S.; Kahn, C.R. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J. Clin. Invest., 1991, 87, 1286-94.
33. McNeill, J.H.; Yuen, V.G.; Hoveyda, H.R.; Orvig, C. Bis(maltolato)oxovanadium(IV) is a potent insulin mimic. J. Med. Chem., 1992, 35, 1489-91.
34. Thompson, K.H.; McNeill, J.H.; Orvig, C. Vanadium compounds as insulin mimics. Chem. Rev., 1999, 99, 2561-72.
35. Reul, B.A.; Amin, S.S.; Buchet, J.P.; Ongemba, L.N.; Crans, D.C.; Brichard, S.M. Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats. Br. J. Pharmacol., 1999, 126, 467-477
36. Goldwaser, I.; Qian, S.; Gershonov, E.; Fridkin, M.; Shechter, Y. Organic vanadium chelators potentiate vanadium-evoked glucose metabolism in vitro and in vivo: establishing criteria for optimal chelators. Mol. Pharmacol., 2000; 58, 738-746.
37. Crans, D.C.; Tracey, A.S. In: Vanadium compounds: Chemistry, Biochemistry, and Therapeutic Applications, Tracey, A.S.; Crans, D.C., Eds.; American Chemical Society Symposium Series 711: Washington DC, 1998, pp. 2-29.
38. Thompson, K.H.; Orvig, C. Metal complexes in medicinal chemistry: new vistas and challenges in drug design. Dalton Trans., 2006, 761-764.
39. Goldwaser, I.; Li, J.; Gershonov, E.; Armoni, M.; Karnieli, E.; Fridkin, M.; Shechter, Y. l-Glutamic Acid -monohydroxamate a potentiator of vanadium-evoked glucose metabolism in vitro and in vivo. J. Biol. Chem., 1999, 274, 26617-26624.
40. Barrio, D.A.; Cattaneo, E.R.; Apezteguia, M.C.; Etcheverry, S.B. Vanadyl(IV) complexes with saccharides. Bioactivity in osteoblastlike cells in culture. Can. J. Physiol. Pharmacol., 2006, 84, 765-75.
41. Williams, P.A.; Etcheverry, S.B.; Barrio, D.A.; Baran, E.J. Synthesis, characterization, and biological activity of oxovanadium(IV) complexes with polyalcohols. Carbohydr. Res., 2006, 341, 717-24.
42. Rivadeneira, J.; Barrio, D.A.; Etcheverry, S.B.; Baran, E.J. Spectroscopic characterization of a VO2+ complex of oxodiacetic acid and its bioactivity on osteoblast-like cells in culture. Biol. Trace Elem. Res., 2007, 118, 159-66.
43. Ashiq, U.; Ara, R.; Mahroof-Tahir, M.; Maqsood, Z.T.; Khan, K.M.; Khan, S.N.; Siddiqui, H.; Choudhary, M.I. Synthesis, spectroscopy, and biological properties of vanadium(IV)-hydrazide complexes. Chem. Biodivers., 2008, 5, 82-92.
44. Zorzano, A.; Palacin, M.; Marti, L.; Garcia-Vicente, S. Arylalkylamine vanadium salts as new anti-diabetic compounds. J. Inorg. Biochem., 2009, 103, 559-66.
45. Li, M.; Smee, J.J.; Ding, W.; Crans, D.C. Anti-diabetic effects of sodium 4-amino-2,6-dipicolinatodioxovanadium(V) dihydrate in streptozotocin-induced diabetic rats. J. Inorg. Biochem., 2009, 103, 585-9.
46. Smee, J.J.; Epps, J.A.; Ooms, K.; Bolte, S.E.; Polenova, T.; Baruah, B.; Yang, L.; Ding, W.; Li, M.; Willsky, G.R.; la Cour, A.; Anderson, O.P.; Crans, D.C. Chloro-substituted dipicolinate vanadium complexes: synthesis, solution, solid-state, and insulin-enhancing properties. J. Inorg. Biochem., 2009, 103, 575-84.
47. Rangel, M.; Amorim, M.J.; Nunes, A.; Leite, A.; Pereira, E.; de Castro, B.; Sousa, C.; Yoshikawa, Y.; Sakurai, H. Novel 3hydroxy-4-pyridinonato oxidovanadium(IV) complexes to investigate structure/activity relationships. J. Inorg. Biochem., 2009, 103, 496-502.
48. Faneca, H.; Figueiredo, V.A.; Tomaz, I.; Goncalves, G.; Avecilla, F.; Pedroso de Lima, M.C.; Geraldes, C.F.; Pessoa, J.C.; Castro, M.M. Vanadium compounds as therapeutic agents: some chemical and biochemical studies. J. Inorg. Biochem., 2009, 103, 601-8.
49. Rivadeneira, J.; Barrio, D.A.; Arrambide, G.; Gambino, D.; Bruzzone, L.; Etcheverry, S.B. Biological effects of a complex of vanadium(V) with salicylaldehyde semicarbazone in osteoblasts in culture: mechanism of action. J. Inorg. Biochem., 2009, 103, 633-42.
50. Arrambide, G.; Barrio, D.A.; Etcheverry, S.B.; Gambino, D.; Baran, E.J. Spectroscopic Behavior and Biological Activity of K(2)[VO(O (2))NTA].2H (2)O. Biol. Trace Elem. Res., 2010, 136(2), 241-8.
51. Niu, Y.; Liu, W.; Tian, C.; Xie, M.; Gao, L.; Chen, Z.; Chen, X.; Li, L. Effects of bis(alpha-furancarboxylato)oxovanadium(IV) on glucose metabolism in fat-fed/streptozotocin-diabetic rats. Eur. J. Pharmacol., 2007, 572, 213-9.
52. Shukla, R.; Barve, V.; Padhye, S.; Bhonde, R. Reduction of oxidative stress induced vanadium toxicity by complexing with a flavonoid, quercetin: a pragmatic therapeutic approach for diabetes. Biometals, 2006, 19, 685-93.
53. Yuen, V.G.; Orvig, C.; McNeill, J.H. Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV). Can. J. Physiol. Pharmacol., 1993, 71, 263-9.
54. Yuen, V.G.; Orvig, C.; Thompson, K.H.; McNeill, J.H. Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium(IV). Can. J. Physiol. Pharmacol., 1993, 71, 270-6.
55. Cohen, N.; Halberstam, M.; Shlimovich, P.; Chang, C.J.; Shamoon, H.; Rossetti, L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest., 1995, 95, 2501-9.
56. Goldfine, A.B.; Simonson, D.C.; Folli, F.; Patti, M.E.; Kahn, C.R. Metabolic effects of sodium metavanadate in humans with insulindependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. J. Clin. Endocrinol. Metab., 1995, 80, 3311-20.
57. Halberstam, M.; Cohen, N.; Shlimovich, P.; Rossetti, L.; Shamoon, H. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes, 1996, 45, 659-66.
58. Boden, G.; Chen, X.; Ruiz, J.; van Rossum, G.D.; Turco, S. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism, 1996, 45, 1130-1135.
59. Cusi, K.; Cukier, S.; DeFronzo, R.A.; Torres, M.; Puchulu, F.M.; Redondo, J.C. Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. J. Clin. Endocrinol. Metab., 2001, 86, 1410-7.
60. Goldfine, A.B.; Willsky, G.; Kahn, C.R. In: Vanadium Compounds. Chemistry, biochemistry, and therapeutic applications, Tracey, A.S. and Crans, D.C. Ed.; American Chemical Society Series 711: Washington, DC, 1998, pp. 353-368.
61. Thompson, K.H.; Orvig, C. Vanadium in Diabetes: 100 years from Phase 0 to Phase I. J. Inorg. Biochem., 2006, 100, 1925-1935.
62. Thompson, K.H.; Lichter, J.; LeBel, C.; Scaife, M.C.; McNeill, J.H.; Orvig, C. Vanadium treatment of type 2 diabetes: A view to the future. J. Inorg. Biochem., 2009, 103, 554-558.
63. Orvig, C.; Thompson, K.H.; Liboiron, B.D.; McNeill, J.H; Yuen, V.G.; Biolocalization and in vivo coordination chemistry of vanadium pharmaceuticals. J. Inorg. Biochem., 2003, 96, 14.
64. Thompson, K.H.; Liboiron, B.D.; Sun, y.; Bellman, K.D.D.; Setyawati, I.A; Patrick, B.O.; Karunaratne, V.; Rawji, G.; Wheeler, J.; Sutton, K.; Bhanot, S.; Cassidy, C.; McNeill, J.H.; Yuen V.G.; Orvig, C. Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of antidiabetic therapeutic potential. J. Biol. Inorg. Chem., 2003, 8, 66-74.
65. Hori, C.; Oka, T. Vanadate enhances the stimulatory action of insulin on DNA synthesis in cultured mouse mammary gland. Biochim. Biophys. Acta, 1980, 610, 235-40.
66. Smith, J.B. Vanadiumions stimulate DNA synthesis in Swiss mouse 3T3 and 3T6 cells. Proc. Natl. Acad. Sci., 1983, 80, 6162-6.
67. Canalis, E. Effect of growth factors on bone cell replication and differentiation. Clin. Orthop., 1985, 193, 246-63.
68. Lau, K.H.; Tanimoto, H.; Baylink, D.J. Vanadate stimulates bone cell proliferation and bone collagen synthesis in vitro. Endocrinology, 1988, 123, 2858-67.
69. Kato, A.; Takagi, T. Estimation of the molecular weight distribution of heat-induced ovalbumin aggregates by the low-angle laser light scattering technique combined with high-performance gel chromatography. J. Agric. Food Chem., 1987, 35, 633-644.
70. Davidai, G.; Lee, A.; Schvartz, I.; Hazum, E. PDGF induces tyrosine phosphorylation in osteoblast-like cells: relevance to mitogenesis. Am. J. Physiol., 1992, 263, E205-E209.
71. Etcheverry, S.B.; Cortizo, A.M. Vanadium Bioactivity on Cells in Culture. In: Vanadium Compounds. Chemistry, Biochemistry, and Therapeutic Applications, Tracey A. and Crans DC, Eds.; American Chemical Society Symposium Series 711: Washington, DC, 1998, pp. 270-276.
72. Tamura, S.; Brown, T.A.; Whipple, J.H.; Fujita-Yamaguchi, Y.; Dubler, R.E.; Cheng, K.; Larner, J. A novel mechanism for the insulin-like effect of vanadate on glycogen synthase in rat adipocytes. J. Biol. Chem., 1984, 259, 6650-8.
73. Green, A. The insulin-like effect of sodium vanadate on adipocyte glucose transport is mediated at a post-insulin-receptor level. Biochem. J., 1986, 238, 663-9.
74. Shisheva, A.; Shechter, Y. A cytosolic protein tyrosine kinase in rat adipocytes. FEBS Lett., 1992, 300, 93-6.
75. Dehghani, G.A.; Ahmadi, S.; Omrani, G.R. Effects of vanadyl sulphate on glucose homeostasis in severe diabetes induced by streptozotocin in rats. Indian J. Med. Res., 1997, 106, 481-5.
76. Singh, J.; Nordlie, R.C.; Jorgenson, R.A. Vanadate: a potent inhibitor of multifunctional glucose-6-phosphatase. Biochim. Biophys. Acta, 1981, 678, 477-82.
77. Swarup, G.; Cohen, S.; Garbers, D.L. Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochem. Biophys. Res. Commun., 1982, 107, 1104-9.
78. Tracey, A.S.; Gresser, M.J. Interaction of vanadate with phenol and tyrosine: implications for the effects of vanadate on systems regulated by tyrosine phosphorylation. Proc. Natl. Acad. Sci., 1986, 83, 609-13.
79. Mohammad, A.; Wang, J.; McNeill, J.H. Bis(maltolato)oxovanadium(IV) inhibits the activity of PTP1B in Zucker rat skeletal muscle in vivo. Mol. Cell Biochem., 2002, 229, 125-8.
80. Peters, K.G.; Davis, M.G.; Howard, B.W.; Pokross, M.; Rastogi, V.; Diven, C.; Greis, K.D.; Eby-Wilkens, E.; Maier, M.; Evdokimov, A.; Soper, S.; Genbauffe, F. Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component. J. Inorg. Biochem., 2003, 96, 321-30.
81. Tamura, S.; Brown, T.A.; Dubler, R.E.; Larner, J. Insulin-like effect of vanadate on adipocyte glycogen synthase and on phosphorylation of 95,000 dalton subunit of insulin receptor. Biochem. Biophys. Res. Commun., 1983, 113, 80-6.
82. D'Onofrio, F.; Le, M.Q.; Chiasson, J.L.; Srivastava, A.K. Activation of mitogen activated protein (MAP) kinases by vanadate is independent of insulin receptor autophosphorylation. FEBS Lett., 1994, 340, 269-375.
83. Posner, B.I.; Faure, R.; Burgess, J.W.; Bevan, A.P.; Lachance, D.; Zhang-Sun, G.; Fantus, I.G.; Ng, J.B.; Hall, D.A.; Lum, B.S.; et al. Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J. Biol. Chem., 1994, 269, 4596-604.
84. Pandey, S.K.; Chiasson, J.L.; Srivastava, A.K. Vanadium salts stimulate mitogen-activated protein (MAP) kinases and ribosomal S6 kinases. Mol. Cell Biochem., 1995, 153, 69-78.
85. Shechter, Y.; Li, J.; Meyerovitch, J.; Gefel, D.; Bruck, R.; Elberg, G.; Miller, D.S.; Shisheva, A. Insulin-like actions of vanadate are mediated in an insulin-receptor-independent manner via nonreceptor protein tyrosine kinases and protein phosphotyrosine phosphatases. Mol. Cell Biochem., 1995, 153, 39-47.
86. Srivastava, A.K.; Pandey, S.K. Potential mechanism(s) involved in the regulation of glycogen synthesis by insulin. Mol. Cell Biochem., 1998, 182, 135-41.
87. Mehdi, M.Z.; Srivastava, A.K. Organo-vanadium compounds are potent activators of the protein kinase B signaling pathway and protein tyrosine phosphorylation: Mechanism of insulinomimesis. Arch. Biochem. Biophys., 2005; 440, 158-64.
88. Pandey, S.K.; Theberge, J.F.; Bernier, M.; Srivastava, A.K. Phosphatidylinositol 3-kinase requirement in activation of the ras/C-raf1/MEK/ERK and p70(s6k) signaling cascade by the insulinomimetic agent vanadyl sulfate. Biochemistry, 1999, 38, 1466775.
89. Chaudhary, L.R.; Avioli, L.V. Identification and activation of mitogen-activated protein (MAP) kinase in normal human osteoblastic and bone marrow stromal cells: attenuation of MAP kinase activation by cAMP, parathyroid hormone and forskolin. Mol. Cell. Biochem., 1998, 178, 59-68.
90. Zhen, X.; Bonjour, J.P.; Caverzasio, J. Platelet-derived growth factor stimulates sodium-dependent Pi transport in osteoblastic cells via phospholipase Cgamma and phosphatidylinositol 3' kinase. J. Bone Miner. Res., 1997, 12, 36-44.
91. Kawane, T.; Horiuchi, N. Insulin-like growth factor I suppresses parathyroid hormone (PTH)/PTH-related protein receptor expression via a mitogen-activated protein kinase pathway in UMR-106 osteoblast-like cells. Endocrinology, 1999, 140, 871-9.
92. Xia, Z.; Dickens, M.; Raingeaud, J.; Davis, R.J.; Greenberg, M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science, 1995, 270, 1326-31.
93. Etcheverry, S.B.; Williams, P.A.; Salice, V.C.; Barrio, D.A.; Ferrer, E.G.; Cortizo, A.M. Biochemical properties and mechanism of action of a vanadyl(IV)-aspirin complex on bone cell lines in culture. Biometals, 2002, 15, 37-49.
94. Barrio, D.A.; Williams, P.A.; Cortizo, A.M.; Etcheverry, S.B. Synthesis of a new vanadyl(IV) complex with trehalose (TreVO): insulin-mimetic activities in osteoblast-like cells in culture. J. Biol. Inorg. Chem., 2003, 8, 459-68.
95. Molinuevo, M.S.; Barrio, D.A.; Cortizo, A.M.; Etcheverry, S.B. Antitumoral properties of two new vanadyl(IV) complexes in osteoblasts in culture: role of apoptosis and oxidative stress. Cancer Chemother. Pharmacol., 2004, 53, 163-72.
96. Cortizo, A.M.; Molinuevo, M.S.; Barrio, D.A.; Bruzzone, L. Osteogenic activity of vanadyl(IV)-ascorbate complex: evaluation of its mechanism of action. Int. J. Biochem. Cell. Biol., 2006, 38, 1171-80.
97. Sekar, N.; Li, J.; Shechter, Y. Vanadium salts as insulin substitutes: mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research. Crit. Rev. Biochem. Mol. Biol., 1996, 31, 339-59.
98. Elberg, G.; He, Z.; Li, J.; Sekar, N.; Shechter, Y. Vanadate activates membranous nonreceptor protein tyrosine kinase in rat adipocytes. Diabetes, 1997, 46, 1684-90.
99. Theberge, J.F.; Mehdi, M.Z.; Pandey, S.K.; Srivastava, A.K. Prolongation of insulin-induced activation of mitogen-activated protein kinases ERK 1/2 and phosphatidylinositol 3-kinase by vanadyl sulfate, a protein tyrosine phosphatase inhibitor. Arch. Biochem. Biophys., 2003, 420, 9-17.
100. Sekar, N.; Li, J.; He, Z.; Gefel, D.; Shechter, Y. Independent signal-transduction pathways for vanadate and for insulin in the activation of glycogen synthase and glycogenesis in rat adipocytes. Endocrinology, 1999, 140, 1125-31.
101. Mongold, J.J.; Cros, G.H.; Vian, L.; Tep, A.; Ramanadham, S.; Siou, G.; Diaz, J.; McNeill, J.H.; Serrano, J.J. Toxicological aspects of vanadyl sulphate on diabetic rats: effects on vanadium levels and pancreatic B-cell morphology. Pharmacol. Toxicol., 1990, 67, 192-8.
102. Ramanadham, S.; Heyliger, C.; Gresser, M.J.; Tracey, A.S.; McNeill, J.H. The distribution and half-life for retention of vanadium in the organs of normal and diabetic rats orally fed vanadium(IV) and vanadium(V). Biol. Trace Elem. Res., 1991, 30, 11924.
103. Dai, S.; Thompson, K.H.; Vera, E.; McNeill, J.H. Toxicity studies on one-year treatment of non-diabetic and streptozotocin-diabetic rats with vanadyl sulphate. Pharmacol. Toxicol., 1994, 75, 265-73.
104. Amano, R.; Enomoto, S.; Nobuta, M.; Sakamoto, M.; Tsujioka, R.; Ambe, F. Bone uptake of vanadium in mice: simultaneous tracing of V, Se, Sr, Y, Zr, Ru and Rh using a radioactive multitracer. J. Trace Elem. Med. Biol., 1996, 10, 145-8.
105. Setyawati, I.A.; Thompson, K.H.; Yuen, V.G.; Sun, Y.; Battell, M.; Lyster, D.M.; Vo, C.; Ruth, T.J.; Zeisler, S.; McNeill, J.H.; Orvig, C. Kinetic analysis and comparison of uptake, distribution, and excretion of 48V-labeled compounds in rats. J. Appl. Physiol., 1998, 84, 569-75.
106. Kartsogiannis, V.; Ng, K. W. Cell lines and primary cell cultures in the study of bone cell biology. Mol. Cell. Endocrinol., 2004, 228,79-102.
107. Anke M.; Groppel B.; Krause U. In: Trace Elements in Man and Animals, Momcilovic B. Eds.; IMI: Zagreb, 1991, Vol. 7, pp. 9-10.
108. Rygh, O. Recherches sur les oligo-elements; de l'importance du thallium, du vanadium, du silicium et du fluor. Bull. Soc. chim. Boil., 1949, 31, 1403-1407.
109. Gresser, M.J.; Tracey, A.S. In: Vanadium in Biological Systems. Chasteen N.D, Ed.; Kluwer Academic Publishers: Dordrecht, The Netherlands, 1990, pp. 63-79.
110. Crans, D. C. Aqueous chemistry of labile oxovanadates of relevance to biological studies. Comm. Inorg. Chem., 1994; 16, 35-76.
111. Bhattacharyya, S.; Tracey, A.S. Vanadium(V) complexes in enzyme systems: aqueous chemistry, inhibition and molecular modeling in inhibitor design. J. Inorg. Biochem., 2001, 85, 9-13.
112. Etcheverry, S.B.; Apella, M.C.; Baran, E.J. A model study of the incorporation of vanadium in bone. J. Inorg. Biochem., 1984, 20, 269-74.
113. Apella, M.C.; Etcheverry, S.B.; Baran, E.J. Untersuchung der symmetrischen Phosphat-Valenzschwingung in gemischten Calcium-Strontium-Apatiten. Z. Naturforsch, 1981; 36b, 1190-1192.
114. Narda, G.E.; Pedregosa, J.C.; Etcheverry, S.B.; Baran, E.J. Schwingungsspektroskopische Untersuchung einiger gemischter Calcium/Cadmium-Hydroxylapatite. Z. Naturforsch, 1990; 45b, 1133-1135
115. Uthus, E.O.; Nielsen, F.H. Effect of vanadium, iodine and their interaction on growth, blood variables, liver trace elements and thyroid status indices in rats. Magnes. Trace Elem., 1990, 9, 219-26.
116. Nemsadze, O.D. Effect of the trace element vanadium on reparative regeneration of bone tissue in the mandible. Stomatologia (Mosk), 1977, 56, 1-5.
117. Krieger, N.S.; Tashjian, A.H. Jr Inhibition of stimulated bone resorption by vanadate. Endocrinology, 1983, 113, 324-8.
118. Etcheverry, S.B.; Crans, D.C.; Keramidas, A.D.; Cortizo, A.M. Insulin-mimetic action of vanadium compounds on osteoblast-like cells in culture. Arch. Biochem. Biophys., 1997, 338, 7-14.
119. Salice, V.C.; Cortizo, A.M.; Gomez Dumm, C.L.; Etcheverry, S.B. Tyrosine phosphorylation and morphological transformation induced by four vanadium compounds on MC3T3E1 cells. Mol. Cell Biochem., 1999, 198, 119-28.
120. Barrio, D.A.; Braziunas, M.D.; Etcheverry, S.B.; Cortizo, A.M. Maltol complexes of vanadium (IV) and (V) regulate in vitro alkaline phosphatase activity and osteoblast-like cell growth. J. Trace Elem. Med. Biol., 1997, 11, 110-5.
121. Crans, D.C.; Smee, J.J. Gaidamauskas, E.; Yang, L. The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds. Chem. Rev., 2004, 104, 849-902.
122. Etcheverry, S.B.; Barrio, D.A.; Williams, P.A.; Baran, E.J. On the interaction of the vanadyl(IV) cation with lactose: inhibition effects of vanadyl(IV)/monosaccharide and disaccharide complexes upon alkaline phosphatase activity. Biol. Trace Elem. Res., 2001, 84, 227-38.
123. Tiago, D.M.; Laize, V.; Cancela, M.L.; Aureliano, M. Impairment of mineralization by metavanadate and decavanadate solutions in a fish bone-derived cell line. Cell Biol. Toxicol., 2008, 24, 253-63.
124. Etcheverry, S.B.; Barrio, D.A.; Cortizo, A.M.; Williams, P.A. Three new vanadyl(IV) complexes with non-steroidal antiinflammatory drugs (Ibuprofen, Naproxen and Tolmetin). Bioactivity on osteoblastlike cells in culture. J. Inorg. Biochem., 2002, 88, 94-100.
125. Etcheverry, S.B.; Barrio, D.A. In: Vanadium: The versatile element, Kustin, K.; Costa Pesoa, J.; Crans, D.C. Eds.; American Chemical Society: Washington, D.C, 2007; Vol. 15, 204-216.
126. Poucheret, P.; Verma, S.; Grynpas, M.D.; McNeill, J.H. Vanadium and diabetes. Mol. Cell Biochem., 1998, 188, 73-80.
127. Facchini, D.M.; Yuen, V.G.; Battell, M.L.; McNeill, J.H.; Grynpas, M.D. The effects of vanadium treatment on bone in diabetic and non-diabetic rats. Bone, 2006, 38, 368-77.
128. Zhang, S.Q.; Chen, G.H.; Lu, W.L.; Zhang, Q. Effects on the bones of vanadyl acetylacetonate by oral administration: a comparison study in diabetic rats. J. Bone Miner. Metab., 2007, 25, 293-301.
129. Etcheverry, S.B.; Williams, P.A.; Barrio, D.A.; Salice, V.C.; Ferrer, E.G.; Cortizo, A.M. Synthesis, characterization and bioactivity of a new VO2+/aspirin complex. J. Inorg. Biochem., 2000, 80, 16971.
130. Cortizo, A.M.; Salice, V.C.; Vescina, C.M.; Etcheverry, S.B. Proliferative and morphological changes induced by vanadium compounds on Swiss 3T3 fibroblasts. Biometals, 1997, 10, 127-33.
131. Shisheva, A.; Shechter, Y. Role of cytosolic tyrosine kinase in mediating insulin-like actions of vanadate in rat adipocytes. J. Biol. Chem., 1993, 268, 6463-9.
132. Eldar-Finkelman, H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med., 2002, 8, 126-32.
133. Reedijk, P.H.M. Lohman Cisplatin: synthesis, antitumour activity and mechanism of action pharmacy. World Sci., 1985, 7, 173-180.
134. Boven E, van der Vijgh WJ, Nauta MM, Schlüper HM, Pinedo HM. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res., 1985, 45, 86-90.
135. Farrell, N.P. In: Uses of Inorganic Chemistry in Medicine, Farrell, N.P. Ed.; The Royal Society of Chemistry: Cambridge, UK, 1999, pp. 16.
136. Holko, P.; Ligeza, J.; Kisielewska, J.; Kordowiak, A.M.; Klein, A. The effect of vanadyl sulphate (VOSO4) on autocrine growth of human epithelial cancer cell lines. Pol. J. Pathol., 2008, 59, 3-8.
137. Klein, A.; Holko, P.; Ligeza, J.; Kordowiak, A.M. Sodium orthovanadate affects growth of some human epithelial cancer cells (A549, HTB44, DU145). Folia Biol. Krakow, 2008, 56, 115-21.
138. Hanauske, U.; Hanauske, A.R.; Marshall, M.H.; Muggia, V.A.; Von Hoff, D.D. Biphasic effect of vanadium salts on in vitro tumor colony growth. Int. J. Cell. Cloning., 1987, 5, 170-8.
139. Djordjevic, C. In: Metal Ions in Biological Systems. Vanadium and its role in life, Sigel, H.; Sigel, A. Eds.; Marcel Dekker, INC: New York. 1995, pp. 595-615.
140. Cruz, T.F.; Morgan, A.; Min, W. In vitro and in vivo antineoplastic effects of orthovanadate. Mol. Cell Biochem., 1995, 153, 161-6.
141. Milarski, K.L.; Saltiel, A.R. Expression of catalytically inactive Syp phosphatase in 3T3 cells blocks stimulation of mitogenactivated protein kinase by insulin. J. Biol. Chem., 1994, 269, 21239-43.
142. Xiao, S.; Rose, D.W.; Sasaoka, T.; Maegawa, H.; Burke, T.R. Jr; Roller, P.P.; Shoelson, S.E.; Olefsky, J.M. Syp (SH-PTP2) is a positive mediator of growth factor-stimulated mitogenic signal transduction. J. Biol. Chem., 1994, 269, 21244-8.
143. Baratte, B.; Meijer, L.; Galaktionov, K.; Beach, D. Screening for antimitotic compounds using the cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2/cyclin Bcdc13 protein kinase. Anticancer Res., 1992, 12, 873-80.
144. Hamaguchi, T.; Sudo, T.; Osada, H. RK-682, a potent inhibitor of tyrosine phosphatase, arrested the mammalian cell cycle progression at G1phase. FEBS Lett., 1995, 372, 54-8.
145. Faure, R.; Vincent, M.; Dufour, M.; Shaver, A.; Posner, B.I. Arrest at the G2/M transition of the cell cycle by protein-tyrosine phosphatase inhibition: studies on a neuronal and a glial cell line. J. Cell. Biochem., 1995, 59, 389-401.
146. Scrivens, P.J.; Alaoui-Jamali, M.A.; Giannini, G.; Wang, T.; Loignon, M.; Batist, G.; Sandor, V.A. Cdc25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analogues. Mol. Cancer Ther., 2003, 2, 1053-9.
147. Zhang, Z.; Huang, C.; Li, J.; Leonard, S.S.; Lanciotti, R.; Butterworth, L.; Shi, X. Vanadate-induced cell growth regulation and the role of reactive oxygen species. Arch. Biochem. Biophys., 2001, 392, 311-20.
148. Zhang, Z.; Chen, F.; Huang, C.; Shi, X. Vanadate induces G2/M phase arrest in p53-deficient mouse embryo fibroblasts. J. Environ. Pathol. Toxicol. Oncol., 2002, 21, 223-31.
149. Farinelli, S.E.; Greene, L.A. Cell cycle blockers mimosine, ciclopirox, and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support. J. Neurosci., 1996, 16, 1150-62.
150. D'Cruz, O.J.; Uckun, F.M. Metvan: a novel oxovanadium(IV) complex with broad spectrum anticancer activity. Expert Opin. Investig. Drugs, 2002, 11, 1829-36.
151. Molinuelo, M.S.; Cortizo, A.M.; Etcheverry, S.B. Vanadium(IV) complexes inhibit adhesion, migration and colony formation of UMR106 osteosarcoma cells. Cancer Chemother. Pharmacol., 2008, 61,767-73.
152. Hamilton, E.E.; Fautch, J.M.; Gentry, S.M.; Wilker, J.J. In: Vanadium: The versatile metal, Kustin, K., Costa Pesoa, J.; Crans, D.C. Eds.; American Chemical Society, Washington, D.C., 2007, pp. 296-309.
153. Thompson, H.J.; Chasteen, N.D.; Meeker, L.D. Dietary vanadyl(IV) sulfate inhibits chemically-induced mammary carcinogenesis. Carcinogenesis, 1984, 5, 849-51.
154. Bishayee, A.; Chatterjee, M. Inhibition of altered liver cell foci and persistent nodule growth by vanadium during diethylnitrosamineinduced hepatocarcinogenesis in rats. Anticancer Res., 1995, 15, 455-61.
155. Bishayee, A.; Chatterjee, M. Inhibitory effect of vanadium on rat liver carcinogenesis initiated with diethylnitrosamine and promoted by phenobarbital. Br. J. Cancer, 1995, 71, 1214-20.
156. Bishayee, A.; Oinam, S.; Basu, M.; Chatterjee, M. Vanadium chemoprevention of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinogenesis: probable involvement of representative hepatic phase I and II xenobiotic metabolizing enzymes. Breast Cancer Res. Treat., 2000, 63, 133-45.
157. Basak, R.; Saha, B.K.; Chatterjee, M. Inhibition of diethylnitrosamine-induced rat liver chromosomal aberrations and DNA-strand breaks by synergistic supplementation of vanadium and 1alpha,25dihydroxyvitamin D(3). Biochim. Biophys. Acta, 2000, 1502, 273-82.
158. Chakraborty, A.; Selvaraj, S. Differential modulation of xenobiotic metabolizing enzymes by vanadium during diethylnitrosamineinduced hepatocarcinogenesis in Sprague-Dawley rats. Neoplasma, 2000, 47, 81-9.
159. Samanta, S.; Chatterjee, M.; Ghosh, B.; Rajkumar, M.; Rana, A.; Chatterjee, M. Vanadium and 1, 25 (OH)2 vitamin D3 combination in inhibitions of 1,2, dimethylhydrazine-induced rat colon carcinogenesis. Biochim. Biophys. Acta, 2008, 1780, 1106-14.
160. Samanta, S.; Swamy, V.; Suresh, D.; Rajkumar, M.; Rana, B.; Rana, A.; Chatterjee, M. Protective effects of vanadium against DMH-induced genotoxicity and carcinogenesis in rat colon: removal of O(6)-methylguanine DNA adducts, p53 expression, inducible nitric oxide synthase downregulation and apoptotic induction. Mutat. Res., 2008, 650, 123-31.
161. Verma, S.; Cam, M.C.; McNeill, J.H. Nutritional factors that can favorably influence the glucose/insulin system: vanadium. J. Am. Coll. Nutr., 1998, 17, 11-8.
162. Bhuiyan, M.S.; Takada, Y.; Shioda, N.; Moriguchi, S.; Kasahara, J.; Fukunaga, K. Cardioprotective effect of vanadyl sulfate on ischemia/reperfusion-induced injury in rat heart in vivo is mediated by activation of protein kinase B and induction of FLICEinhibitory protein. Cardiovasc. Ther., 2008, 26, 10-23.
163. Bhuiyan M.S.; Shioda, N.; Fukunaga, F. Targeting protein kinase B/Akt signaling with vanadium compounds for cardioprotection. Expert Opin. Ther. Targets, 2008, 12, 1217-1227.
164. Bhanot, S.; Michoulas, A.; McNeill, J.H. Antihypertensive effects of vanadium compounds in hyperinsulinemic, hypertensive rats. Mol. Cell. Biochem., 1995, 153, 205-9.
165. Jeliki-Stankov, M.; Uskokovi-Markovi, S.; HolclajtnerAntunovi, I., Todorovi, M.; Djurdjevi, P. Compounds of Mo, V and W in biochemistry and their biomedical activity. J. Trace Elem. Med. Biol., 2007; 21, 8-16.
166. Matsui, T.; Li, L.; del Monte F.; Fukui, Y.; Franke, T.F.; Hajjar, R.J.; Rosenzweig, A. Adenoviral gene transfer of activated phosphatidylinositol 3'-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation, 1999, 100, 2373-9.
167. Takada, Y.; Hashimoto, M.; Kasahara, J.; Aihara, K.; Fukunaga, K. Cytoprotective effect of sodium orthovanadate on ischemia/reperfusion-induced injury in the rat heart involves Akt activation and inhibition of fodrin breakdown and apoptosis. J. Pharmacol. Exp. Ther., 2004, 311, 1249-55.
168. Bhuiyan, M.S.; Shioda, N.; Shibuya, M.; Iwabuchi, Y.; Fukunaga, K. Activation of endothelial nitric oxide synthase by a vanadium compound ameliorates pressure overload-induced cardiac injury in ovariectomized rats. Hypertension, 2009, 53, 57-63.
169. Cadene, A.; Grigorescu, F.; Serrano, J.J.; Cros, G. Characterization of vanadyl sulfate effect on vascular contraction: roles of calcium and tyrosine phosphorylation. J. Pharmacol. Exp. Ther., 1997, 281, 491-8.
170. Carr, A.N.; Davis, M.G.; Eby-Wilkens, E.; Howard, B.W.; Towne, B.A.; Dufresne, T.E.; Peters, K.G. Tyrosine phosphatase inhibition augments collateral blood flow in a rat model of peripheral vascular disease. Am. J. Physiol. Heart Circ. Physiol., 2004, 287, H268-76.
171. Shah, D.I.; Singh, M. Inhibition of protein tyrosin phosphatase improves vascular endothelial dysfunction. Vasc. Pharmacol., 2006, 44, 177-82.
172. Cortizo, A.M.; Caporossi, M.; Lettieri, G.; Etcheverry, S.B. Vanadate-induced nitric oxide production: role in osteoblast growth and differentiation. Eur. J. Pharmacol., 2000, 400, 279-85.
173. Papapetropoulos, A.; Fulton, D.; Lin, M.I.; Fontana, J.; McCabe, T.J.; Zoellner, S.; Garcia-Cardena, G.; Zhou, Z.; Gratton, J.P.; Sessa, W.C. Vanadate is a potent activator of endothelial nitricoxide synthase: evidence for the role of the serine/threonine kinase Akt and the 90-kDa heat shock protein. Mol. Pharmacol., 2004, 65, 407-15.
174. Bhanot, S.; Bryer-Ash, M.; Cheung, A.; McNeill, J.H. Bis(maltolato)oxovanadium(IV) attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats. Diabetes, 1994, 43, 857-61.
175. Bhanot, S.; McNeill, J.H. Vanadyl sulfate lowers plasma insulin and blood pressure in spontaneously hypertensive rats. Hypertension, 1994, 24, 625-32.
176. Bhanot, S.; McNeill, J.H.; Bryer-Ash, M. Vanadyl sulfate prevents fructose-induced hyperinsulinemia and hypertension in rats. Hypertension, 1994, 23, 308-12.
177. Fujio, Y.; Nguyen, T.; Wencker, D.; Kitsis, R.N.; Walsh, K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation, 2000, 101, 660-7.